The entire team behind the Harvard Biomarkers Study (HBS) expresses their sincere gratitude to participants of the Harvard Biomarker Study and heartfelt appreciation for your commitment to advancing Parkinson's disease (PD) research through your participation over the years. Patient involvement has played a crucial role in contributing to our understanding of biomarkers and their significance in the context of Parkinson's disease. HBS is continuing its vital work, focusing on the identification and analysis of biomarkers that could significantly impact the diagnosis and treatment of PD. The study remains dedicated to pushing the boundaries of scientific knowledge and improving the lives of individuals affected by this condition.
As part of the ongoing evolution of the study, we would like to inform you of a transition in leadership. Dr. Clemens Scherzer has made significant contributions during his tenure as the principal investigator, including outstanding research strides and collaborations, both nationally and internationally. Moving forward, Dr. Vikram Khurana will be leading the study into its next chapter, The Harvard Biomarkers Study 2.0, bringing with him a wealth of expertise and dedication to advancing Parkinson's research. Additionally, the study will continue to be managed by Dr. Daniel El Kodsi, ensuring a seamless transition, and maintaining the high standards set by the Harvard Biomarkers Study. Presented is a compelling opportunity to not just uphold essential elements of HBS, but also integrate with other vital components within the field of movement division, including Dr. Khurana's MyTrial clinical trial incubator and the addition of imaging techniques (MRI/PET ligand), in collaboration with the Institute for Neurodegenerative Diseases.
Contacts
Dr. Daniel El Kodsi - delkodsi@bwh.harvard.edu
Grace Greco - ggreco@bwh.harvard.edu or at (857) 307-5424
We look forward to your continued involvement in the Harvard Biomarkers Study and the positive impact it will undoubtedly have on the lives of those affected by Parkinson's disease.
